Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy Clinical Trial

Official title:
Long-Term Follow-Up of Subjects Treated With NTLA-2001

Status Recruiting

Clinical Trial Summary

This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Amyloid Neuropathies
Amyloid Neuropathies, Familial
Amyloidosis
Cardiomyopathies
Polyneuropathies
Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

Clinical Trial Details

NCT number	NCT05697861
Study type	Observational
Source	Intellia Therapeutics
Contact	Trial Manager at Intellia
Phone	1-833-888-0387
Email	clinicalscience@intelliatx.com
Status	Recruiting
Phase
Start date	July 10, 2023
Completion date	March 2038

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04882735` - Efficacy and Safety of Acoramidis (AG10) in Subjects With Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)	Phase 3
Withdrawn	`NCT04418024` - Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Polyneurophathy	Phase 3
Active, not recruiting	`NCT04601051` - Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)	Phase 1
Recruiting	`NCT03237494` - TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
Withdrawn	`NCT02713880` - Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)